ArticleJournal of clinical immunology2023

CXCL9 as a Reliable Biomarker for Discriminating Anti-IFN-γ-Autoantibody-Associated Lymphadenopathy that Mimics Lymphoma.

Chang-Tsu Yuan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.